DiGAs on the rise - Viatris and HiDoc with partnership

Viatris and HiDoc Technologies are working together to improve the care of patients with irritable bowel syndrome. To this end, they are relying on "Cara Care for Irritable Bowel Syndrome", the first approved digital health application for this therapeutic area.

The digital health startup HiDoc Technologies GmbH and the pharmaceutical company Viatris are working together to commercialize the DiGA "Cara Care for Irritable Bowel Syndrome". The aim is to improve care for the millions of people affected in Germany. The partnership is part of Viatris' strategy to focus on gastrointestinal diseases.

The partnership with Viatris will combine our digital development know-how with Viatris' commercial expertise and infrastructure in a targeted manner

James Mapes, CEO HiDoc Technologies

Irritable bowel syndrome is a common intestinal disorder that affects around 11 million people in Germany. Symptoms such as abdominal pain, constipation, diarrhea, flatulence and bloating affect the quality of life of those affected. Although comprehensive treatment is recommended, only around 20% seek medical help.

Cara Care for Irritable Bowel Syndrome is a digital health application (DiGA) that is approved as a medical device and is available to people with irritable bowel syndrome. The application is accessible via a mobile app and offers personalized multimodal therapy based on nutritional and behavioral approaches as well as gut-related hypnosis. The application is available on prescription and can be reimbursed by statutory and some private health insurance companies.

Digital health applications

Digital health applications (DiGAs) are on the rise in Germany. These digital medical products support the detection and treatment of diseases or the individual implementation of treatment processes. For around three years now, they have been fully prescribable and reimbursable for people with statutory health insurance, provided that the Federal Institute for Drugs and Medical Devices (BfArM) confirms a positive effect on care. The so-called apps on prescription have now established themselves in patient care in many places. Following successful testing, 43 DiGAs are currently listed as reimbursable (DiGA). The Digital Healthcare Act (DVG), which has been in force since December 2019, serves as the legal basis. An overview of the approved DiGAs can be found in the directory of the Federal Institute for Drugs and Medical Devices.

About Vitaris

Viatris Inc. is a global healthcare company that aims to provide access to quality medicines and vaccines to people worldwide. Established in November 2020, the company has expertise in science, manufacturing and distribution to serve patients in over 165 countries. Its portfolio comprises more than 1,400 molecules across a broad range of therapeutic areas, including non-communicable and infectious diseases, as well as premium branded and generic products. The company has approximately 37,000 employees worldwide and is headquartered in the US, with global headquarters in Pittsburgh, Shanghai and Hyderabad. More information is available on their website and social media channels.

The Viatris Group Germany consists of several companies: Viatris Healthcare GmbH, Viatris Pharma GmbH, Mylan Germany GmbH and MEDA Pharma GmbH & Co. KG. The production facility of Madaus GmbH is located in Troisdorf and the Viatris Collaboration Hub Berlin rounds off the portfolio.